Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050973 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
A Phase 3 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 623
- Enrollment target
NCT00050973 is a Phase 3 study that has completed, run by Eisai. The registered enrollment target is 623 participants.
The verdict
NCT00050973, a Phase 3 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 623 participants
- Enrollment target
Study Summary
This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.
Interventions
- DRUG bexarotene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 623 participants |
| Est. Completion | 2005-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050973
The ClinicalTrials.gov registry entry for NCT00050973 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 623 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bexarotene is the first listed.
NCT00050973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050973 about?
NCT00050973 is a clinical study titled "Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer". This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.
What is the current status of trial NCT00050973?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 623 participants. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00050973?
The interventions under investigation include: bexarotene (DRUG).
Who is sponsoring clinical trial NCT00050973?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.